Radar Caídas · 54/100 · Ready to research
54/100The chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.
Links you can open and check yourself, most reliable first. Internal data-provider fetches are not listed here.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
The stock fell 14.8%. There is a recent company event that could be related to the drop (Publicación de resultados del segundo trimestre de 2026 y presentaciones en SEC (8‑K y 10‑Q) el 3 de agosto de 2026; la prensa recoge titulares mixtos: beneficio por acción superior pero ingresos por debajo de algunas previsiones. dated 3 August 2026), but we could not confirm it happened before the drop began.
This 70% is the confidence the model states about its own analysis after reviewing the sources.
Verified data: 7 of 10 checks have real data.
The market appears to be pricing in the risk of a slowdown in revenue growth following the August 3, 2026, report. The reaction centers on headlines that combine reported earnings per share above consensus with signs of revenue falling short of some forecasts, which has triggered a price drop of nearly 15% in 48 hours.
! Partly justified
The ~14.8% drop over 48 hours coincides with headlines citing weaker revenue, which is cause for some concern. However, the objective data in the report show a solid balance sheet: net cash of 814.3 MUSD and positive free cash flow of 137.5 MUSD (reported figures), in addition to a majority of analysts with a buy recommendation (9 buy, 1 hold). In other words, while there are reasons to penalize the weak revenue, the company’s financial health limits the risk of immediate structural damage.
The sources do not provide a clear figure quantifying the direct cost of the catalyst on the company’s value (e.g., a fine or one-time charge). Therefore, the quantifiable impact is considered undeterminable based on the data provided (0%), and the gap is the actual decline of 14.82 percentage points, which indicates a moderate overreaction according to the internal method.
Management clarifies during the call or in a statement that the decline in revenue was due to temporary timing factors and confirms or raises its operating forecasts for the rest of the year; analysts maintain or raise their estimates.
The company releases additional information explaining that the dip was a one-time occurrence (e.g., sales timing or accounting effects), maintains its cost structure, and demonstrates stable cash generation in subsequent reports.
Either the next quarterly report will confirm that the revenue slowdown is persistent, or the company will announce that it needs significant capital.
Horizon: 0–7 days
Horizon: 0–14 days
Horizon: 7–30 days
No verifiable comparable cases were saved for this page.
The score is computed by Python code from objective data, not by the AI model, and it does not change after the qualitative research.
Values used by this framework's Python scoring engine at detection time. Only indicators the data source could confirm are shown.
Why some numbers are coloured and others stay grey
Colour repeats what the sign already says, at three intensities depending on how far the value is from zero. It is never the only signal.
Everything whose sign is not good or bad on its own stays grey: valuation (a low P/E can be a bargain or a trap, and almost every company here has just fallen), debt, size, insider ownership and short interest. Those are shown as-is, without the site taking a view.
The drop in the stock price appears to be an overreaction to a mixed quarterly report: according to press reports, the company reported earnings per share that beat the consensus, but some reports indicate revenue fell short of expectations; the balance sheet shows significant net cash and positive cash flow, so the actual impact on solvency and business operations appears limited.
Release of second-quarter 2026 results and SEC filings (8-K and 10-Q) on August 3, 2026; the press reports mixed headlines: earnings per share were higher, but revenue fell short of some forecasts. | Next month
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ... · 3 August 2026
We don't judge whether it's good or bad news: compare it against the real return since detection in the table below.
Tracking ended 30 days after detection (Radar Caídas policy): the last recorded data point is the 1-month one, it is not updated further.